CD4 CELLS PROFILE OF HAART NAIVE HIV SEROPOSITIVE C

LIENTS IN KOGI 

STATE UNIVERSITY TEACHING HOSPITAL, ANYIGBA, KOGI S

TATE. NIGERIA by Alabi,, O. J et al.
190 
 
ORIGINAL ARTICLE  
AFRICAN JOURNAL OF CLINICAL AND EXPERIMENTAL MICROBIOLOGY   JULY  2016   ISBN 1595-689X      VOL17 No. 3   
AJCEM/1628    http://www.ajol.info/journals/ajcem                 
COPYRIGHT 2016     http://dx.doi.org/10.4314/ajcem.v17i3.6 
AFR. J. CLN. EXPER. MICROBIOL. 17 (3): 190-196 
 
CD4 CELLS PROFILE OF HAART NAIVE HIV SEROPOSITIVE CLIENTS IN KOGI 
STATE UNIVERSITY TEACHING HOSPITAL, ANYIGBA, KOGI STATE. NIGERIA 
1.Alabi, O. J.; 2.Akogu, S.P.O.; . 3Akpa,  M.; 4 Ukeje,  V.; 5Okpanachi P.O; 6 Agama O.G; 7Gideon, S.; 8Adegboro, B. 
1Department of Community Medicine, Kogi State University, Anyigba.  2Department of Physiology 
Kogi State University, Anyigba; 3Department of Obstetrics and Gynaecology, Kogi State University Teaching Hospital, 
Anyigba.  4,5,6Department of Pathology, Kogi State University Teaching Hospital, Anyigba. Kogi state; 7Gideon, S, Department 
of Biochemistry, Kogi state University, Anyigba; 8Adegboro,B, Department of Microbiology, Kogi State University, Anyigba. 
Kogi State. Nigeria. 
1Correspondence:     Dr Alabi Oladele Joshua, Department of Community Medicine, Kogi State University, Anyigba. Kogi State.  
Email: alabioladele2008@yahoo.com Phone Number + 2347030813771 
 ABSTRACT 
CD4 lymphocyte cells are the primary targets of Human immune-deficiency virus (HIV). Enumeration of CD4 T lymphocytes in 
the peripheral blood is used in the assessment of disease clinical stage, risk of opportunistic infections, evaluation of prognosis 
and guide decision on the commencement of antiretroviral therapy. The objective was to determine CD4 cells profile of HIV 
sero-positive naïve patients in Kogi State University Teaching Hospital( KSUTH) Anyigba. A total of 404 HIV sero-positive 
Highly Active Anti Retro Viral Treatment ( HAART) naïve patients comprising 147(36.4%) males and 257 (63.6%) females were 
examined. Approval was obtained from ethical committee of Kogi State University Teaching Hospital (KSUTH), Anyigba. 
Written and verbal informed consent was taken from all patients. The overall mean age of patients was 33.0 ± 12.7 years and 
female-male ratio was 1.7:1. Majority of patients were in the clinical stage two 121(30.5%) and three 200(50.4%).  Patients had 
overall mean CD4 cells count of 381.8 ± 240.8 cells /mm3. Patients CD4 cells count varied statistically with the HIV clinical 
staging (F =4.512 & P value=0.004) and statistically insignificant with gender (P value = 0.7562 & t Test= 0.3106) and tuberculosis 
status (P value=0.223 & F= 1.505).Conclusion: This study showed HIV sero-positive HAART naive patients presented in KSUTH 
with mean age of 33 years. Majority of patients presented in disease clinical stage two and three with a mean CD4 cells counts of 
381.8 cells/mm3 . This study recommend the need to reduce stigmatization, discrimination and promote early access to treatment 
, care and support services. 
Keywords: HIV/AIDS, CD4, Patient/clients, KSUTH, Nigeria. 
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RESUME 
La colonisation de la plaie par des microorganismes est le plus souvent poly microbiennes et l’incidence de haut niveau de la 
résistance par des isolats de plaies ont été rapportés. Staphylocoque aureus résistant à la Méthicilline (SARM) et bêta–Lactamases 
spectre étendu (BLSE) produisant des bactéries à Gram – négatif, les deux constituent  un sérieux défi  pour le médecin 
dans le choix du traitement antibiotique des infections causées par ces bactéries. Cette étude a déterminé les profils de sensibilité 
aux antibiotiques et la prévalence des producteurs de SARM et BLSE parmi les isolats bactériens des plaies d’un hôpital tertiaire dans 
la ville d’Ibadan. Quarante (40) isolats bactériens clinique provenant de cinq sources de plaies ont été recueillis de l’unité de 
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microbiologie de l’University College Hospital (UCH), Ibadan et ont été authentifiés avec des techniques bactériologiques 
standard. Test de sensibilité aux antibiotiques a fait par  la  méthode de diffusion  sur  disque  en utilisant  19 antibiotiques 
appartiennent à 12 classes. Les souches SARM ont été détectés par la résistance aux antibiotiques cefoxitin et /ou oxacilline. La 
production de BLSE présomptif était par le test de synergie double dique en utilisant 30µg cefotaxime et ceftaxidime autour de 20/10 
µg disques d’acide amoxicilline – clavunique. La confirmation de BLSE a été par  la  concentration  minimale inhibitrice (CMI) en 
utilisant agar   -   méthode de dilution. Les isolats authentifiés comprennent Proteus spp (47,5%), Staphylococcus   aureus   (27,5%),   
Pseudomonas aeruginosa (12,5%), Klebsiella spp (7,5%), Acinetobacter baumannii (2,5%),et E. Coli (2,5%). 
La distribution des isolats collectés selon des sources de plaies comprend : plaies  aigües   des tissus mous (35%) ,  ulcère   de 
jambe,(32%) les plaies chirurgicales (17,5%), les plaies de brule (12,5%)et les ulcères du pied diabétique (2,5%). La répartition 
selon le sexe des patients  sont : male(65%), femelle (35%), selon les groupes d’âge sont :0 – 19 ans (22,5%),20 – 39ans (35%), 40 –59 ans 
(32,5%) et ≥ 60 ans (10%). Tous (100%) les isolats étaient multiresistants    (MDR) e t a n t    resistant    a   ≥     3   classes 
d’antibiotiques. Les pourcentage de la résistance des isolats à chaque  antibiotique   comprend :   piperacilline,   piperacilline   - 
tozobactam et acide amoxicilline – clavulanique etaient 100%, ceftazidime, cefuroxime, cefixime, aztreonam, sulphamethoxazole – 
trimethoprim, erythromycin, chloramphenicol et doxycyline etaient  >70%, cefoxitin  (62,5%), nitrofurantoïne (52,5%), ciprofloxacine 
(45%), l’ofloxacine (35%),perfloxacin (37,5%),  gentamicine  (32,5%), et imipénème (2,5%). Du 11 Staphylocoque  aereus recueillis, 
54,5% ont été détectés comme des souches de SARM alors que la production de BLSE a été détectée dans 55,2% des isolats 
Gram négatif. Cette étude a révélé 100% phénotype constituant un niveau élevé des   souches de SARM (54,5%) et les 
producteurs  de BLSE (55,2%) chez les Gram – positif et Gram – négatif des isolats bactérien de plaies. Par conséquent, il faut 
la prudence dans l’utilisation des antibiotiques à spectre étendu dans le traitement des patients avec plaies infectées. 
 
INTRODUCTION                                                                                                                                                                              
Human immunodeficiency virus (HIV) is a virus 
belonging to retroviridae family and a member of the 
lent virus genus. HIV causes human 
immunodeficiency viral infection that could progress 
to acquired immune deficiency syndrome (AIDS) 
(1,2).  According to World Health Organization in 
2013 about 35 million people worldwide were living 
with HIV, while 2.1 million people had new infection 
and 12.9 million people had access to antiretroviral 
drugs. The AIDS related deaths globally occurred 
among 1.5 million people (3,4).  In Nigeria, about 3.2 
million people in 2013  were reported by United 
Nations Agency for International 
Development(UNAIDS) to be living with HIV, while 
210,000 deaths occurred from AIDS related illnesses 
and 2 million orphans aged 0-17 years were estimated 
from AIDS (5). CD4 lymphocyte cells (also known 
and called T cells or T helper cells) are the primary 
targets of HIV (6). CD4 is a glycoprotein found on the 
surface of immune cells such as T helper cells, 
monocytes, macrophages and dendritic cells (7).  CD4 
T lymphocyte cells are white blood cells. They 
perform  essential functions in the coordination of the 
immune response, the body defense reaction against 
microorganisms and some form of cancer. A CD4 
count is a laboratory test that is measured directly by 
flow cytometry (8-11). The pathogenesis of HIV 
/AIDS is largely attributable to the decrease in T 
lymphocytes bearing the CD4 receptor. Progressive 
depletion of CD4+ T lymphocytes is associated with 
an increased likelihood of clinical complication 
including the development of AIDS.  
 
 
 
The enumeration of CD4+ T lymphocytes in the 
peripheral blood is an essential tool for the laboratory 
monitoring of HIV infected patients. Currently 
available CD4+ T cells counting techniques are 
automated method using flow cytometry and the 
dedicated cytometers. Other techniques include 
manual assays using microscope or ELISA equipment 
(8-14).  A CD4 T cells count measure the number of 
CD4 cells pre micro liter (ul) of blood in a sample (13-
15).  It is used in HIV infection to determine the 
clinical stage of the disease, assess the risk of 
opportunistic infections, evaluate prognosis and 
guide decisions on the commencement of anti 
retroviral therapy and drugs for opportunistic 
infections (16-19).   In adults, absolute numbers of 
CD4 T cells are measured; while in infants and young 
children the relative CD4 cells among the total 
lymphocytes (CD4 percentage) is a more informative 
indicator of disease status.  Determination of CD4 T 
lymphocyte count is affected by time of day, fatigue 
and stress (20-22).  Other factors such as age, gender, 
race, socio economic, smoking, alcohol consumption, 
nutrition , infection and antiretroviral therapy have 
been identified as important determinants (20-22).  
The objectives of the study was to determine the 
profile of CD4 T lymphocyte of HIV sero-positive 
clients that attended Kogi state University Teaching 
Hospital Kogi State university Teaching Hospital 
(KSUTH) Anyigba, Kogi state ,Nigeria between 
January 1, 2014 to December 31,2014. 
MATERIALS AND METHODS 
Materials used were Partec Cyflow Counter 
Cylometer, Partec Cleaning sheath and 
decontamination fluids. Other materials include 
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Partec CD4 and CD4% easy count kits, Rohrentubes, 
pipettes, tubes rack, EDTA tubes (5mls), Jik solution, 
Determine HIV Test kits with LOT number 59098k100 
and Unigold HIV test kits with LOT number 3110061. 
The research design was a prospective experimental 
study. Ethical approval was obtained from the ethical 
committee of the Kogi state university teaching 
hospital, Anyigba, Kogi state, Nigeria. 
Four hundred and four (404) clients who attended 
Kogi state university teaching hospital Anyigba 
between January 1, 2014 and December 31, 2014; and 
tested seropositive for Human Immunodeficiency 
Virus after screening with Determines and Ungold 
HIV test kits were examined.   Verbal and written 
informed consent was obtained from all patients. 
History and examination was conducted on each 
patient to obtain biodata, weight, clinical staging and 
risk of pulmonary tuberculosis. Flow cytometry using 
Partec Cyflow Counter Flow Cylometer was used to 
determine CD4 T lymphocyte and  CD4 percentage 
(23-25). 5mls whole blood sample was collected from 
each patient between 8.00 am to 10.00 am by 
venipuncture into 5ml  vacutainer tubes containing 
EDTA. 20microliter of whole blood with EDTA as 
coagulant was added to a partec rohren tube. 
Addition 20 micro liter of Partec CD4 easy count kit 
was also added to the tube. The tube was incubated 
for 15 minutes at room temperature protected from 
light. 800 micro liter of no lyse Partec CD4 buffer was 
added(26). Slight shaking or vortex turning was done. 
Analysis of blood samples on the Cyflow Counter 
Cylometer was conducted after fixation of rohren 
tube on the sample pot. Statistical package for social 
sciences version 20 was used for data analysis. The 
study was predetermined at P value < 0.05 and 95% 
confidential interval. Data were generated into cross 
tabulations and descriptive statistics, T test and 
Analysis of Variance (ANOVA) were conducted. 
RESULT                                                                               
A total of 404 HIV seropositive naïve patients 
comprising 147 (36.4%) males and 257(63.6%) females 
were evaluated in this survey. The age distribution of 
patients was 140 (34.7%) in the 30-39 years, followed 
by 125 (30.9%) in the 20-29yrs, and 64 (15.8%) in the 
40-49 years. The overall mean age of patients was 33.0 
± 12.7 years. The mean age of female patient was 
31.7± 10.9 years, while that of the males was 35.1 ± 
15.0 years. Patients’ main ethnicity was Igala 382( 
94.6%), which was followed by Ibo 17 (4.2%) and 
other tribes. Patients belonged predominantly to HIV 
clinical stage three 200 (50.4%) and stage two 121 
(30.5%) and were not tuberculosis suspect 367 
(90.8%). The overall mean CD4 count of patients was 
381.8± 240.8 cells/mm3.The mean CD4 count of 
female patients was 384.4 ± 245. O cells /mm3, while 
that of male respondents was 377.2 ± 181.9 cells 
/mm3. Patients’ CD4 cells count varied statistically 
with the HIV clinical staging (F=4.512 and P value 
=0.004) and statistically insignificant with gender (P 
value=0.7562, T test= 0.3106) and tuberculosis status ( 
P value = 0.223 and F = 1.505). 
TABLE 1:   DISTRIBUTION OF RESPONDENTS BY 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS 
           A.       Age Distribution of Respondents: 
                      Age (yrs)                            Frequency (%) 
                                  0-9                                        22(5.4) 
                                 10-19                                    13(3.2) 
                                20.29                                     125(30.9) 
                                30-39                                     140(34.7) 
                                40-49                                     64(15.8) 
                                50-59                                     28(6.9) 
                                >60                                         12(3.0) 
                               Total                                       404(100.0) 
           B.           Gender Distribution of Respondents: 
                       Gender                            Frequency (%)        
                             Male                                       147(36.4) 
                             Female                                   257(63.6) 
                            Total                                       404(100.0) 
          C.           Distribution of Respondents by ethnicity: 
                            Ethnicity                         Frequency (%) 
                            Igala                                         382(94.6) 
                            Yoruba                                     2(0.5 
                            Ibo                                           17(4.2) 
                            Hausa                                      1(0.2) 
                           Other                                        2(0.5 
                           Total                                         404(100.0) 
         D.           Distribution of Respondents by HIV clinic  
                        Disease staging :  
                           Clinic Stage                    Frequency (%) 
             1                                               72(18.1 
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                             2                                               121(30.9) 
                             3                                               200(50.4) 
                             4                                              11(2.7) 
                           Total                                         404(100.0) 
       E.                Distribution of Respondents by HIV     
                           clinical disease stage::                                  
                          Tuberculosis(TB) status          Frequency ( %) 
                          TB Negative                                367 (90.8) 
                          TB suspect                                  36(8.9) 
                          TB exposed  on INH 
                          Prophylaxis                               1( 0.3) 
                          Total                                          404(100.0) 
  
 
DISCUSSION 
The mean age distribution of HIV sero-positive naïve 
patients in this study lied in the third decade of life. 
The mean age group distributed in the very active 
reproductive life, characterized by risky behavior 
such as unprotected sex, multiple sexual partners, 
alcoholism, smoking, intravenous drug addiction and 
body tattoo practices which predisposes to HIV 
infection. The finding of this survey on the age group 
distribution of HIV sero-positive HAART naive 
patients were collaborated by several researchers (27-
31). The age group above 60 years like in other studies 
recorded least patients which can be attributed to 
interplay of non sexual risky behavior in that age 
group category (28,29). The female male ratio 
recorded in this study was 1.7:1.   
 
 
TABLE 2:    STATISTICAL SUMMARY 
 
 
       Mean CD4 count                    =      381.800 
       Standard  deviation                =       240.8 
       Standard Error of the mean    =       11.980 
       Total Respondents(N)                   404 
       T test of one sample               =      31.8691 
       Degree of freedom                 =       403 
       P value                                   =      0.0001 
 
Observations of higher distribution of HIV among 
female patients were collaborated by Omoti and 
Akinbami etal in their previous studied (32-33). 
Several reasons such as early marriage, polygamous 
relationship, occurrence of pelvic inflammatory 
diseases and genital ulcers were deduced by many 
researchers for the higher occurrence of HIV 
seropositive clients among female gender(34-36).   
Variant gender findings with predominant male 
distribution was recorded by Oguejiofor and Glynn et 
al in their separate studied (37-38).  However, equal 
male-female ratio was observed by Nwozor and 
Nwankwo in Akwa, South East, Nigeria (29).  This 
study showed that majority of patients belonged to 
Igala tribe, which is the main ethnicity of the people 
in the community where the health facility is located. 
Most patients presented in the health facility in the 
disease clinical stage two and three. low awareness, 
rejection, fear of stigmatization, cultural belief and 
tradio-medical patronage were among many reasons 
deduced for the late presentation and access of HIV 
treatment care and support programmes available in 
health facilities.  
TABLE 3: DISTRIBUTION OF CD4 COUNT OF PATIENTS BY HIV/AIDS CLINICAL STAGE 
 
CLINICAL STAGE        NUMBER OF SUBJECT          MEAN       SD        TOTAL DF       F           P VALUE 
          1                                                   72                     464.6       258.0           403           4.512           0.004  
          2                                                 121                     390.9        219.7  
          3                                                  200                     346.0       238.5 
          4                                                  11                      390.9       242.9 
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TABLE 4: GENDER DISTRIBUTION OF CD4 COUNT OF RESPONDENTS. 
 
GENDER       MEAN       SD          PATIENTS NUMBER       P VALUE         T                     DF              SE 
Male              377.2          181.9                     147                           0.7562        0.3106               402            23.179 
Female         384.4          245.0                     257 
Total            381.8          240.8                     404 
 
 
TABLE 5: DISTRIBUTION OF RESPONDENTS BY CD4 COUNT AND TB STATUS 
 
TB STATUS                                 MEAN            SD                PATIENTS NUMBER (N)    DF          F               P VALUE 
 TB Negative                              383.9            237.2                           367(90.8)                     403         1.505           0.223 
 TB Suspect                               350.0            268.7                            36(8.9) 
 TB Exposed on INH                  750                 0                                1(0.3) 
 
The overall mean CD4 cell counts of 381.8 cells/mm3 
in this study collaborated similar reports from 
previous surveys in countries with low resource 
setting that many patients only seek medical attention 
and are diagnosed when HIV infection becomes 
complicated by AIDS defining illnesses (27,28).   
Patients’ CD4 cells distribution varied statistically 
with disease clinical stage (P value =0.004 and F = 
4.512) as were found in similar researches(36-37).  
High HIV coupling in acquires immunodeficiency 
syndrome is reported with low CD4 cells count in 
some studies(5,6,9,16-17).  In this study, gender and 
tuberculosis status of patients were found to be 
statistically insignificant which was at variant with 
observations from similar studies(21, 27,29-38). 
Under reporting, cultural belief and tradio-medical 
care in traditional centers of tuberculosis related 
illnesses may accounts for the insignificant nature of 
the tuberculosis status on the CD4 cells count.      
 CONCLUSION: This study showed HIV sero-
positive HAART naive patients presented in KSUTH 
with mean age of 33 years and female preponderance.  
Majority of patients were in disease clinical stage two 
and three with a mean CD4 cell counts of 381.8 
cells/mm3. This study showed the need for awareness 
campaigns to reduce stigmatization, discrimination, 
rejection suffered by patients and stepping up HIV 
counseling, testing  and access to care and treatment 
programme. 
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